Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Go West, mein Herr

OXFORD-Ever since 1996, when Jürgen Rüttgers, then German federal minister for research, science, technology and education, unveiled his ambitious BioRegio program to stimulate biotech entrepreneurship, critics warned that it would never lead to sustainable companies. But those critics now may find themselves having to eat their words, as two of Rüttgers' babies today planned to announce that they are acquiring U.S. companies.

In both cases, easier access to capital at robust valuations in Germany last year paved the way for the transatlantic deals. And although the financing dynamics now have changed, the argument for European companies to go global promises to remain.

GPC AG (Munich, Germany), a genomics-based drug discovery company, was to announce that it is acquiring Mitotix Inc. (Cambridge, Mass.), a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections.

Separately, Morphochem AG (Munich), a drug discovery company, was to disclose

Read the full 1460 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE